Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liting Xue

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Frontiers in Oncology|June 1, 2022
Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 InhibitorsPeng Gu, Liting Xue, Chunyan Zhao, et al.
Blood|May 23, 2012
Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signalingJohn Anto Pulikkan, Dmitri Madera, Liting Xue, et al.
Molecular Cancer Therapeutics|April 21, 2026
PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian CancerGuimei Yang, Huixia Dou, Liting Xue, et al.
Molecular Cancer Therapeutics|April 21, 2026
PRMT5 inhibition by SCR-6920 downregulates HIF-1α and exhibits synergistic antitumor activity with bevacizumab in ovarian cancerGuimei Yang, Huixia Dou, Liting Xue, et al.
Medcomm|September 23, 2024
SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the <i>S</i>-adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumorsZhiyong Yu, Yi Kuang, Liting Xue, et al.
International Immunopharmacology|July 21, 2024
Technical considerations and strategies for generating and optimizing humanized mouse tumor models in immuno-oncology researchWenjing Li, Chunlei Xia, Kun Wang, et al.
Science Translational Medicine|September 5, 2014
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemiaLeyuan Ma, Yi Shan, Robert Bai, et al.
Science (New York, N.Y.)|February 14, 2015
Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in miceAnuradha Illendula, John A Pulikkan, Hongliang Zong, et al.
Journal of Medicinal Chemistry|December 30, 2025
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer TherapyWei Zhu, Lei Jiang, Dongxing Zhu, et al.
Journal of Neurology|February 7, 2026
JAK2 pathogenic variants in ischemic stroke: low prevalence and pre-screening modelJialu Zhao, Siqi Ge, Shujun Gao, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Frontiers in Oncology|June 1, 2022
Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 InhibitorsPeng Gu, Liting Xue, Chunyan Zhao, et al.
Blood|May 23, 2012
Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signalingJohn Anto Pulikkan, Dmitri Madera, Liting Xue, et al.
Molecular Cancer Therapeutics|April 21, 2026
PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian CancerGuimei Yang, Huixia Dou, Liting Xue, et al.
Molecular Cancer Therapeutics|April 21, 2026
PRMT5 inhibition by SCR-6920 downregulates HIF-1α and exhibits synergistic antitumor activity with bevacizumab in ovarian cancerGuimei Yang, Huixia Dou, Liting Xue, et al.
Medcomm|September 23, 2024
SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the <i>S</i>-adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumorsZhiyong Yu, Yi Kuang, Liting Xue, et al.
International Immunopharmacology|July 21, 2024
Technical considerations and strategies for generating and optimizing humanized mouse tumor models in immuno-oncology researchWenjing Li, Chunlei Xia, Kun Wang, et al.
Science Translational Medicine|September 5, 2014
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemiaLeyuan Ma, Yi Shan, Robert Bai, et al.
Science (New York, N.Y.)|February 14, 2015
Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in miceAnuradha Illendula, John A Pulikkan, Hongliang Zong, et al.
Journal of Medicinal Chemistry|December 30, 2025
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer TherapyWei Zhu, Lei Jiang, Dongxing Zhu, et al.
Journal of Neurology|February 7, 2026
JAK2 pathogenic variants in ischemic stroke: low prevalence and pre-screening modelJialu Zhao, Siqi Ge, Shujun Gao, et al.
Pageof 2